Czech National Bank Has $31.99 Million Stock Holdings in Danaher Co. (NYSE:DHR)

Czech National Bank lifted its position in shares of Danaher Co. (NYSE:DHR) by 6.4% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 139,378 shares of the conglomerate’s stock after buying an additional 8,439 shares during the quarter. Czech National Bank’s holdings in Danaher were worth $31,994,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Teachers Insurance & Annuity Association of America bought a new stake in Danaher in the 3rd quarter valued at about $39,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Danaher in the third quarter valued at approximately $40,000. FSA Wealth Management LLC bought a new stake in shares of Danaher in the third quarter valued at approximately $50,000. Darwin Wealth Management LLC acquired a new stake in Danaher during the third quarter worth approximately $55,000. Finally, Dunhill Financial LLC increased its stake in Danaher by 45.1% during the 3rd quarter. Dunhill Financial LLC now owns 222 shares of the conglomerate’s stock worth $62,000 after acquiring an additional 69 shares during the period. Institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

DHR has been the subject of several analyst reports. Stifel Nicolaus boosted their target price on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research report on Wednesday, October 23rd. Scotiabank started coverage on Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price target for the company. TD Cowen lifted their target price on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Finally, Evercore ISI raised their price target on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $286.80.

Danaher Trading Down 1.3 %

Shares of DHR stock opened at $235.08 on Monday. The stock has a 50-day moving average of $235.67 and a 200-day moving average of $253.73. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The stock has a market cap of $169.79 billion, a price-to-earnings ratio of 44.86, a PEG ratio of 4.32 and a beta of 0.83. Danaher Co. has a 1-year low of $222.53 and a 1-year high of $281.70.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.02 EPS. On average, equities research analysts forecast that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.46%. Danaher’s payout ratio is 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.